Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy
Abstract Cancer immunotherapy has significantly advanced the treatment paradigm in oncology, with approvals of immuno‐oncology agents for over 16 indications, many of them first line. Checkpoint inhibitors (CPIs) are recognized as an essential backbone for a successful anticancer therapy regimen. Th...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Clinical and Translational Science |
| Online Access: | https://doi.org/10.1111/cts.13312 |
| _version_ | 1828154507081547776 |
|---|---|
| author | Sreeneeranj Kasichayanula Sandhya Mandlekar Vittal Shivva Maulik Patel Sandhya Girish |
| author_facet | Sreeneeranj Kasichayanula Sandhya Mandlekar Vittal Shivva Maulik Patel Sandhya Girish |
| author_sort | Sreeneeranj Kasichayanula |
| collection | DOAJ |
| description | Abstract Cancer immunotherapy has significantly advanced the treatment paradigm in oncology, with approvals of immuno‐oncology agents for over 16 indications, many of them first line. Checkpoint inhibitors (CPIs) are recognized as an essential backbone for a successful anticancer therapy regimen. This review focuses on the US Food and Drug Administration (FDA) regulatory approvals of major CPIs and the evolution of translational advances since their first approval close to a decade ago. In addition, critical preclinical and clinical pharmacology considerations, an overview of the pharmacokinetic and dose/regimen aspects, and a discussion of the future of CPI translational and clinical pharmacology as combination therapy becomes a mainstay of industrial immunotherapy development and in clinical practice are also discussed. |
| first_indexed | 2024-04-11T22:41:01Z |
| format | Article |
| id | doaj.art-e322787f3a6a42109ffe1625db83470c |
| institution | Directory Open Access Journal |
| issn | 1752-8054 1752-8062 |
| language | English |
| last_indexed | 2024-04-11T22:41:01Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Science |
| spelling | doaj.art-e322787f3a6a42109ffe1625db83470c2022-12-22T03:59:00ZengWileyClinical and Translational Science1752-80541752-80622022-08-011581818183710.1111/cts.13312Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapySreeneeranj Kasichayanula0Sandhya Mandlekar1Vittal Shivva2Maulik Patel3Sandhya Girish4Gilead Sciences Foster City California USAGenentech South San Francisco California USAGenentech South San Francisco California USAAbbVie Inc. South San Francisco California USAGilead Sciences Foster City California USAAbstract Cancer immunotherapy has significantly advanced the treatment paradigm in oncology, with approvals of immuno‐oncology agents for over 16 indications, many of them first line. Checkpoint inhibitors (CPIs) are recognized as an essential backbone for a successful anticancer therapy regimen. This review focuses on the US Food and Drug Administration (FDA) regulatory approvals of major CPIs and the evolution of translational advances since their first approval close to a decade ago. In addition, critical preclinical and clinical pharmacology considerations, an overview of the pharmacokinetic and dose/regimen aspects, and a discussion of the future of CPI translational and clinical pharmacology as combination therapy becomes a mainstay of industrial immunotherapy development and in clinical practice are also discussed.https://doi.org/10.1111/cts.13312 |
| spellingShingle | Sreeneeranj Kasichayanula Sandhya Mandlekar Vittal Shivva Maulik Patel Sandhya Girish Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy Clinical and Translational Science |
| title | Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy |
| title_full | Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy |
| title_fullStr | Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy |
| title_full_unstemmed | Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy |
| title_short | Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy |
| title_sort | evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy |
| url | https://doi.org/10.1111/cts.13312 |
| work_keys_str_mv | AT sreeneeranjkasichayanula evolutionofpreclinicalcharacterizationandinsightsintoclinicalpharmacologyofcheckpointinhibitorsapprovedforcancerimmunotherapy AT sandhyamandlekar evolutionofpreclinicalcharacterizationandinsightsintoclinicalpharmacologyofcheckpointinhibitorsapprovedforcancerimmunotherapy AT vittalshivva evolutionofpreclinicalcharacterizationandinsightsintoclinicalpharmacologyofcheckpointinhibitorsapprovedforcancerimmunotherapy AT maulikpatel evolutionofpreclinicalcharacterizationandinsightsintoclinicalpharmacologyofcheckpointinhibitorsapprovedforcancerimmunotherapy AT sandhyagirish evolutionofpreclinicalcharacterizationandinsightsintoclinicalpharmacologyofcheckpointinhibitorsapprovedforcancerimmunotherapy |